• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Marex Group plc Announces Launch of a Public Offering

    4/14/25 4:04:05 PM ET
    $MRX
    Investment Bankers/Brokers/Service
    Finance
    Get the next $MRX alert in real time by email

    NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (NASDAQ:MRX) ("Marex"), the diversified global financial services platform, today announces the launch of a public offering of its ordinary shares (the "Offering") by certain selling shareholders (the "Selling Shareholders"). The Selling Shareholders are offering a total of 8,500,000 ordinary shares. In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,275,000 ordinary shares.

    Marex is not selling any ordinary shares in the Offering and will not receive any proceeds from the sale of shares by the Selling Shareholders.

    Goldman Sachs & Co. LLC, Barclays and Jefferies are acting as lead book-running managers and as representatives of the underwriters for the proposed offering.

    The proposed Offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the proposed Offering may be obtained from:

    • Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: [email protected];
    • Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at [email protected]; or
    • Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by phone at (877) 821-7388, or by email at [email protected].

    A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

    Enquiries please contact:

    Nicola Ratchford / Adam Strachan

    Marex

    +44 (0) 778 654 8889 / +1 (914) 200 2508 | [email protected] / [email protected]

    FTI Consulting US / UK

    +1 (919) 609-9423 / +44 (0) 7776 111 222 | [email protected]



    Primary Logo

    Get the next $MRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRX

    DatePrice TargetRatingAnalyst
    3/10/2025$33.00 → $36.00Buy → Hold
    HSBC Securities
    11/21/2024$33.00Buy
    HSBC Securities
    11/6/2024$34.00Buy
    Citigroup
    5/20/2024$33.00Buy
    Goldman
    5/20/2024$25.00Overweight
    Barclays
    5/20/2024$27.00Overweight
    Piper Sandler
    5/20/2024$27.00Buy
    UBS
    5/20/2024$24.00Buy
    Jefferies
    More analyst ratings